MARKET

ALDX

ALDX

Aldeyra Therapeu
NASDAQ
4.435
+0.035
+0.80%
Opening 10:30 04/12 EDT
OPEN
4.360
PREV CLOSE
4.400
HIGH
4.466
LOW
4.295
VOLUME
111.23K
TURNOVER
0
52 WEEK HIGH
11.97
52 WEEK LOW
1.420
MARKET CAP
261.20M
P/E (TTM)
-6.9634
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ALDX last week (0401-0405)?
Weekly Report · 4d ago
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
NASDAQ · 6d ago
Aldeyra gains as Perceptive Advisors boosts stake
Perceptive Advisors bought more than $1.9B worth of shares of Aldeyra Therapeutics. The company's lead candidate, reproxalap, is developed with AbbVie. Oppenheimer upgraded the stock to Buy from Hold on Wednesday.
Seeking Alpha · 04/04 14:16
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Recent notable insider transactions for penny stocks include Aldeyra Therapeutics, Inc. And Retractable Technologies.
Benzinga · 04/04 10:23
Aldeyra's Dry Eye Disease Drug May Be On Path For FDA Approval -- Market Talk
Aldeyra Therapeutics surges 15% to $4.10 after an upgrade from Oppenheimer. Analyst raises Aldeyra to outperform from perform with a $10 price target. Analyst cites company's development plan for resubmitting dry eye disease treatment reproxalap.
Dow Jones · 04/03 18:38
BUZZ-U.S. STOCKS ON THE MOVE-Identiv, Levi Strauss, cannabis firms
Wall Street's main indexes advanced on Wednesday. Softer-than-expected services sector data offered relief to investors. Dow Jones Industrial Average was up 0.14% at 39,226.61. Top three S&P 500 percentage gainers: GE Aerospace, Caesars Entertainment, Ulta Beauty.
Reuters · 04/03 18:01
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Ulta Beauty, SPAR Group
Spotify, Ulta Beauty, SPAR Group are among the day's top stocks. Wall Street's main indexes swung higher on Wednesday after softer-than-expected services sector data. The Dow Jones Industrial Average was up 0.21% at 39,252.29.
Reuters · 04/03 15:57
Aldeyra Therapeutics Raised to Outperform From Perform by Oppenheimer
Dow Jones · 04/03 14:09
More
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Webull offers Aldeyra Therapeutics Inc stock information, including NASDAQ: ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.